

Our Ref: 137551/2022/GEN/ATGCO01F

23 August 2022

The Directors  
China NT Pharma Group Company Limited  
28th Floor, The Wellington  
198 Wellington Street  
Sheung Wan  
Hong Kong

**Strictly Private & Confidential**

Dear Sirs,

**Re: CHINA NT PHARMA GROUP COMPANY LIMITED (THE "COMPANY") AND ITS  
SUBSIDIARIES (THE "GROUP")**

We refer to the circular of the Company dated 23 August 2022 (the "Circular") in connection with the very substantial acquisition in relation to the licensing of commercialisation rights (the "Very Substantial Acquisition"). Capitalised terms used herein shall have the same meanings as those defined in the Circular unless otherwise defined.

We hereby consent, and confirm that we have not withdrawn our consent, to the issue of the Circular with the inclusion therein of:

1. our report on the discounted cash flow forecast in connection with the valuation of the exclusive rights to commercialise a monoclonal antibody in China and certain Southeast Asia countries (the "commercialisation rights");
2. our report on the discounted cash flow forecast in connection with the valuation of the exclusive rights to commercialise a monoclonal antibody in China and certain Southeast Asia countries (the "commercialisation rights") for purchase price allocation purpose;
3. the references thereto and to ourselves; and
4. the aforementioned reports all in the form and context in which they respectively appear in the Circular.

We hereby consent to these reports referred above and this letter being made available for display as described in Appendix VI to the Circular.

We also confirm that as at the Latest Practicable Date, we did not have: (a) any direct or indirect interest in any assets which have been, since 31 December 2021 (being the date to which the latest published audited consolidated financial statements of the Group were made up) acquired or disposed of by or leased to any member of the Group, or were proposed to be acquired or disposed of by or leased to any member of the Group; or (b) any beneficial interests in the share capital of any member of the Group, or any right (whether legally enforceable or not) to subscribe for or nominate persons to subscribe for securities in any member of the Group.



**MOORE**

Our Ref: 137551/2022/GEN/ATGCO01F

23 August 2022

The Directors  
China NT Pharma Group Company Limited

This letter is solely being issued in connection with the filing of the Circular regarding the Very Substantial Acquisition and not for any other purpose.

Yours faithfully,

YN/cs/cm